These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response. Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599 [TBL] [Abstract][Full Text] [Related]
48. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model. Scott FI; Shah Y; Lasch K; Luo M; Lewis JD Inflamm Bowel Dis; 2018 Jan; 24(2):286-295. PubMed ID: 29361100 [TBL] [Abstract][Full Text] [Related]
49. Biologics in inflammatory bowel disease: what are the data? Côté-Daigneault J; Bouin M; Lahaie R; Colombel JF; Poitras P United European Gastroenterol J; 2015 Oct; 3(5):419-28. PubMed ID: 26535119 [TBL] [Abstract][Full Text] [Related]
50. [Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice]. Shapina MV; Nanaeva BA Ter Arkh; 2020 Apr; 92(2):67-73. PubMed ID: 32598721 [TBL] [Abstract][Full Text] [Related]
51. Current new challenges in the management of ulcerative colitis. Fukuda T; Naganuma M; Kanai T Intest Res; 2019 Jan; 17(1):36-44. PubMed ID: 30678445 [TBL] [Abstract][Full Text] [Related]
52. Induction and maintenance infliximab therapy in children with moderate to severe ulcerative colitis: Retrospective, multicenter study. Iwańczak BM; Kierkuś J; Ryżko J; Szczepanik M; Więcek S; Czaja-Bulsa G; Kacperska M; Korczowski B; Maślana J; Iwańczak F Adv Clin Exp Med; 2017; 26(1):57-61. PubMed ID: 28397433 [TBL] [Abstract][Full Text] [Related]
55. Infliximab and ulcerative colitis. Cottone M; Mocciaro F; Modesto I Expert Opin Biol Ther; 2006 Apr; 6(4):401-8. PubMed ID: 16548766 [TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis. Yokomizo L; Limketkai B; Park KT BMJ Open Gastroenterol; 2016; 3(1):e000093. PubMed ID: 27195130 [TBL] [Abstract][Full Text] [Related]
57. [Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study]. Rutka M; Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Molnár T Orv Hetil; 2016 May; 157(18):706-11. PubMed ID: 27106726 [TBL] [Abstract][Full Text] [Related]
58. A comprehensive review and update on ulcerative colitis Gajendran M; Loganathan P; Jimenez G; Catinella AP; Ng N; Umapathy C; Ziade N; Hashash JG Dis Mon; 2019 Dec; 65(12):100851. PubMed ID: 30837080 [TBL] [Abstract][Full Text] [Related]
59. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Fausel R; Afzali A Ther Clin Risk Manag; 2015; 11():63-73. PubMed ID: 25609972 [TBL] [Abstract][Full Text] [Related]